We are live on ! Find out more
KYTX icon

Kyverna Therapeutics
KYTX

90 hedge funds and large institutions have $762M invested in Kyverna Therapeutics in 2024 Q1 according to their latest regulatory filings, with 90 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

71.21% more ownership

Funds ownership: 0% → 71.21% (+71%)

99% less call options, than puts

Call options by funds: $5K | Put options by funds: $514K

Holders
90
Holders Change
+90
Holders Change %
–
% of All Funds
1.3%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
90
Increased
–
Reduced
–
Closed
–
Calls
$5K
Puts
$514K
Net Calls
-$509K
Net Calls Change
-$509K

Top Buyers

Rank Fund Capital Flow
1
VVA
Vida Ventures Advisors
Massachusetts
+$126M
2
NV
Northpond Ventures
Maryland
+$90.8M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$88.3M
4
RI
RTW Investments
New York
+$51.7M
5
DM
Deerfield Management
New York
+$40.8M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
VVA
1
Vida Ventures Advisors
Massachusetts
$112M +$126M +4,523,924 New
NV
2
Northpond Ventures
Maryland
$80.9M +$90.8M +3,255,426 New
BCLSI
3
Bain Capital Life Sciences Investors
Massachusetts
$78.6M +$88.3M +3,163,868 New
RI
4
RTW Investments
New York
$46M +$51.7M +1,852,711 New
DM
5
Deerfield Management
New York
$36.3M +$40.8M +1,462,337 New
Jennison Associates
6
Jennison Associates
New York
$34.7M +$39M +1,398,659 New
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$23.1M +$25.9M +929,634 New
IHG
8
Insight Holdings Group
New York
$22.7M +$25.5M +912,915 New
CC
9
Commodore Capital
New York
$22.7M +$25.5M +912,189 New
JP Morgan Chase
10
JP Morgan Chase
New York
$21M +$23.6M +844,465 New
BlackRock
11
BlackRock
New York
$18.6M +$20.9M +749,966 New
NHAS
12
Novo Holdings A/S
Denmark
$17.4M +$19.5M +700,000 New
Millennium Management
13
Millennium Management
New York
$17.3M +$19.4M +695,094 New
Janus Henderson Group
14
Janus Henderson Group
United Kingdom
$15M +$16.9M +606,500 New
Wellington Management Group
15
Wellington Management Group
Massachusetts
$14.9M +$16.8M +601,436 New
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$14.3M +$16M +575,000 New
Citadel Advisors
17
Citadel Advisors
Florida
$13M +$14.6M +523,743 New
LGM
18
Logos Global Management
California
$12.4M +$14M +500,000 New
AllianceBernstein
19
AllianceBernstein
Tennessee
$11.8M +$13.3M +475,827 New
ACA
20
Avoro Capital Advisors
New York
$11.8M +$13.3M +475,000 New
Franklin Resources
21
Franklin Resources
California
$11.4M +$12.8M +460,561 New
EC
22
EcoR1 Capital
California
$11.2M +$12.6M +450,000 New
CAM
23
Cormorant Asset Management
Massachusetts
$10.9M +$12.3M +440,000 New
WP
24
Woodline Partners
California
$9.76M +$11M +392,928 New
Vanguard Group
25
Vanguard Group
Pennsylvania
$6.56M +$7.37M +264,215 New
1
2 3 4

KYTX Hedge Fund Activity: Q1 2024 in Review

90 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q1 2024, worth a combined $762M.

Buyers outnumbered sellers: 90 funds opened new KYTX positions and 0 closed out — a net gain of 90 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Vida Ventures Advisors, opening a new position worth an estimated $126M.

  • 90 institutional investors held Kyverna Therapeutics (KYTX) as of Q1 2024, up from 0 in Q4 2023.
  • Funds reported $762M of Kyverna Therapeutics stock for Q1 2024.
  • 90 funds opened new Kyverna Therapeutics positions in Q1 2024 and 0 closed out, a net change of +90 holders.
  • The largest Kyverna Therapeutics buyer in Q1 2024 was Vida Ventures Advisors, an estimated $126M added.

Based on aggregated 13F filings for Q1 2024.